Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPN-100 Safety and Efficacy in Pediatric UCDs Under 6 Years
NCT01347073Phase 3Completed
- Sponsor
- Amgen
- Start
- Jul 2011
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sodium phenylbutyrate in urea cycle disorders (UCD), sponsored by Amgen. Started Jul 2011; status: completed.
02
Drugs
sodium phenylbutyrate
03
Conditions
urea cycle disorders (UCD)
Beyond the preview
Go deeper on NCT01347073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01347073.